- Home
- TYRA
as 12-20-2024 4:00pm EST
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | 812.7M | IPO Year: | 2021 |
| Target Price: | $31.00 | AVG Volume (30 days): | 219.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.24 - $29.60 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Tyra Biosciences Inc. (TYRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kjellson Nina S | TYRA | Director | Nov 25 '24 | Sell | $16.84 | 5,272 | $88,773.10 | 448,692 | |
| RA CAPITAL MANAGEMENT, L.P. | TYRA | Director10% Owner | Nov 8 '24 | Buy | $16.25 | 1,220,681 | $19,836,066.25 | 8,697,956 | |
| Kjellson Nina S | TYRA | Director | Nov 6 '24 | Sell | $17.25 | 74,582 | $1,284,133.32 | 448,692 | |
| Kjellson Nina S | TYRA | Director | Nov 4 '24 | Sell | $16.89 | 11,569 | $194,248.23 | 448,692 | |
| Fuhrman Alan | TYRA | Chief Financial Officer | Oct 30 '24 | Buy | $16.00 | 9,500 | $151,954.40 | 12,849 | |
| Kjellson Nina S | TYRA | Director | Oct 30 '24 | Sell | $16.58 | 138,711 | $2,282,656.07 | 448,692 | |
| Harris Todd | TYRA | President and CEO | Oct 18 '24 | Sell | $27.50 | 62,720 | $1,711,247.20 | 1,369,115 | |
| Harris Todd | TYRA | President and CEO | Oct 15 '24 | Sell | $25.82 | 58,726 | $1,513,271.34 | 1,369,115 | |
| Harris Todd | TYRA | President and CEO | Sep 30 '24 | Sell | $24.00 | 500 | $12,000.00 | 1,369,115 | |
| Harris Todd | TYRA | President and CEO | Sep 23 '24 | Sell | $24.05 | 11,747 | $283,223.24 | 1,369,115 |
Latest Tyra Biosciences Inc. News
TYRA Breaking Stock News: Dive into TYRA Ticker-Specific Updates for Smart Investing
Simply Wall St.
22 days ago
Tyra Biosciences, Inc. (NASDAQ:TYRA) Shares Could Be 43% Below Their Intrinsic Value Estimate
PR Newswire
a month ago
Tyra Biosciences to Present at Upcoming Investor Conferences
PR Newswire
a month ago
Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights
Argus Research
2 months ago
Daily – Vickers Top Buyers & Sellers for 11/04/2024
Simply Wall St.
2 months ago
Chief Financial Officer of Tyra Biosciences Alan Fuhrman Buys 284% More Shares
PR Newswire
2 months ago
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)
MT Newswires
2 months ago
Tyra Biosciences Shares Retreat After Gains Following Positive Clinical Trial Results for TYRA-300
PR Newswire
2 months ago
Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)
Compare TYRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TYRA Tyra Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.